Business Context and Reporting Period
Company: Charles River Laboratories International, Inc. (CRL)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 28, 2025
Business Overview: A leading global non-clinical drug development partner providing research models, discovery and safety assessment services, and manufacturing solutions. The company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Total Revenue | $1,032,135 | $1,026,117 | $2,016,303 | $2,037,677 |
| Operating Income | $100,134 | $151,652 | $174,803 | $277,629 |
| Operating Margin | 9.7% | 14.8% | 8.7% | 13.6% |
| Net Income (Attributable to CRL) | $52,326 | $94,081 | $77,795 | $167,041 |
| Diluted EPS | $1.06 | $1.74 | $1.55 | $3.04 |
| Operating Cash Flow (6M) | $376,300 | $323,423 | ||
| Cash & Equivalents (End of Period) | $182,824 | |||
| Long-Term Debt & Finance Leases | $2,332,374 |
Material Changes vs. Prior Period
- Revenue: Q2 revenue increased 0.6% year-over-year (YoY), driven by growth in Manufacturing and RMS segments, partially offset by a 1.5% decline in DSA due to cautious client spending. Six-month revenue decreased 1.0% YoY.
- Profitability: Operating income declined significantly, dropping 34.0% in Q2 and 37.0% for the six months ended June 28, 2025. Margins compressed due to accelerated amortization, restructuring costs, and higher legal fees.
- Segment Performance:
- RMS: Revenue up 3.3% in Q2; Operating income up 19.5% due to lower impairment charges.
- DSA: Revenue down 1.5% in Q2; Operating income down 11.3% due to volume declines and legal costs.
- Manufacturing: Revenue up 4.4% in Q2; Operating income plummeted 67.6% due to accelerated amortization of intangible assets following the loss of key CDMO customers.
- Restructuring: The company incurred $32.2 million in restructuring costs in Q2 2025 (vs. $17.9 million in Q2 2024), including $28.5 million in asset impairments and site consolidation charges.
- Amortization: Amortization of intangible assets doubled in Q2 to $65.4 million (from $32.3 million) due to accelerated write-downs related to lost customers in the Manufacturing segment.
Guidance, Outlook, and Risks
- Restructuring Outlook: Management expects current and planned restructuring actions to yield approximately $225 million in annualized cost savings, with $175 million impacting fiscal year 2025.
- Backlog: DSA backlog declined slightly to $1.9 billion as of June 28, 2025, from $2.0 billion at year-end 2024, reflecting cautious client spending.
- Legal & Regulatory:
- DOJ/USFWS: Investigations regarding non-human primate (NHP) shipments from Cambodia were closed in July 2025, with shipments cleared for legal entry.
- SEC: An ongoing inquiry regarding NHP sourcing and disclosures remains open; the company is cooperating but cannot predict the outcome or potential penalties.
- Litigation: A securities class action lawsuit was dismissed in July 2024 but is currently on appeal (oral arguments held May 2025). Two derivative lawsuits are stayed pending the class action appeal.
- Market Risks:
- Tariffs: New U.S. tariffs on imports from Vietnam, Mauritius, and China remain in effect, creating uncertainty for supply chain costs.
- Regulatory Shifts: The FDA announced a pilot program to reduce animal testing in preclinical studies using new approach methodologies (NAMs), which could impact long-term demand for animal models.
- Strategic Review: Following a Cooperation Agreement with a major shareholder, the Board is conducting a comprehensive strategic review of the business, which may result in significant transactions or operational changes.
- Capital Allocation: The company repurchased $350.0 million of stock in the first six months of 2025. $549.3 million remains available under the $1.0 billion authorization.
Investor Verification Checklist
- Accelerated Amortization: Verify the specific impact of the $71.0 million accelerated amortization charge in the Manufacturing segment on future earnings and the status of the lost key customers.
- SEC Investigation Status: Monitor updates on the SEC inquiry regarding NHP sourcing, as potential fines or penalties could materially impact financial results.
- Restructuring Execution: Track the realization of the projected $225 million in annualized cost savings against actual operating expenses in subsequent quarters.
- Strategic Review Outcome: Assess the results of the strategic review initiated with Elliott Investment Management, as this could lead to M&A, divestitures, or other structural changes.
- Regulatory Impact of NAMs: Evaluate the long-term risk posed by the FDA's push for non-animal testing methodologies on the core DSA and RMS revenue streams.